Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actelion Q1 net income up
Actelion has reported net revenues of CHF405.6 million for the first quarter of 2009, an increase of 26%, compared to CHF321.6 million for the first quarter of 2008.
Actelion has reported net revenues of CHF405.6 million for the first quarter of 2009, an increase of 26%, compared to CHF321.6 million for the first quarter of 2008.
Net sales for the first quarter of 2009 were $2.01 billion, which included sales from divested businesses of $4 million, as compared to net sales of $2.05 billion
Under the terms of the agreement, Galapagos’s service division BioFocus DPI will perform biology, medicinal chemistry and ADME/PK services for an Opsona drug discovery program. Opsona will make
Pfizer and Medivation, a biopharmaceutical company, have initiated a 12-month, Phase III clinical trial of the investigational drug Dimebon. The study, known as Concert, is designed to evaluate
Gilead Sciences, a biopharmaceutical company, has started enrolling patients in a Phase II clinical trial of its investigational integrase-based, single-tablet, once-daily regimen of elvitegravir, GS 9350 and Truvada
Icagen, a biopharmaceutical company, has presented positive results from its Phase I program for ICA-105665, the company’s lead drug candidate for the treatment of epilepsy and neuropathic pain.
Dendreon, a biotechnology company, has reported positive data from its Protect or P-11 Phase III study suggesting that Provenge induces long-term memory immune responses that are durable and
Revenues for the fourth quarter of 2008 were $843,000, an increase of 231% from the $255,000 reported for the fourth quarter of 2007. Revenues for the full year
For the first quarter of 2009, Illumina reported gross margin of 66.4% compared with 60.2% in the comparable period of 2008. Excluding the effect of the amortization of
Vion Pharmaceuticals has reported that the new drug application for its lead oncology therapeutic Onrigin injection has been accepted for review by the FDA. The NDA presents data